Clinical Trials

Inclusion Criteria:

• Age ≥ 18 years.
• Diagnosis of invasive breast cancer treated with neoadjuvant systemic therapy.
• Surgically resectable disease following neoadjuvant systemic treatment.
• At least one of the following must be true:
  • Received at least 2 weeks of neoadjuvant endocrine therapy;
  • Received at least 2 months of neoadjuvant chemotherapy with suggestion of residual disease on imaging;
  • Began neoadjuvant chemotherapy or endocrine therapy but discontinued due to evidence of progressive disease by MRI, US, or physical examination.
• Provide written informed consent.
• Willing to return to enrolling institution for breast cancer surgery.
• Willingness to provide mandatory blood specimens for future research on breast cancer at Mayo Clinic.
• Willingness to provide mandatory tissue specimens for future research on breast cancer at Mayo Clinic.
• Willingness to provide mandatory tissue specimens for the generation of PDX and organoids to be used future research on breast cancer at Mayo Clinic.

Exclusion Criteria:

• Ineligible for surgery.
• History of prior malignancy < 3 years prior to registration.
• Exceptions for non-melanoma skin cancer, papillary thyroid cancer, non-invasive cancer (e.g., carcinoma in situ of the cervix).

Eligibility last updated 7/25/23. Questions regarding updates should be directed to the study team contact.